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DM1, treatment with IG is an efﬁcacious and cost-saving option compared with ID, 
because Insulin Glargine is associated with a comparable efﬁcacy and lower total costs 
versus ID allowing savings for up to 17.3% per patient-year.
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OBJECTIVES: To evaluate cost-utility of biphasic insulin aspart (BIAsp) compared 
with premixed human insulin (Premix) in type-2 diabetes mellitus. METHODS: A 
cost-utility analysis based on The CORE Diabetes Model was conducted, resulting in 
estimation of total direct costs incurred by the National Health Fund and patients, 
life years gained (LYG) and quality-adjusted life years (QALY). The CORE Diabetes 
Model is a complex tool allowing for evaluation of long term health and economic 
outcomes of different treatment options in diabetes mellitus. It is designed as a Markov 
model using Monte Carlo simulations and is based on a series of interconnected sub-
models representing diabetes complications. Cohort baseline characteristics and base-
line distribution between states in the model were derived from published literature. 
Treatments were deﬁned in the means of a change in HbA1c level and hypoglycaemia 
rates calculated on the base of systematic review of RCTs. Default settings were used 
regarding to transition probabilities and utilities of health states. Costs from the 
NHFpatient perspective were calculated. Time horizon in the model was set to 30 
years or until death. In order to estimate the probability of BIAsp being cost effective 
in Polish setting (threshold about 91,000 PLN) bootstrap simulations were performed. 
RESULTS: Both treatments were comparable in terms of LYG (7.47 for BIAsp and 
7.46 for Premix), but BIAsp yielded higher QALY (5.06 vs. 4.95 for BHI). Costs gener-
ated by BIAsp were 30,079 PLN and by premixed insulin 24,970 PLN. Incremental 
cost per QALY for BIAsp compared with Premixed was 49,425 PLN. Probability of 
BIAsp cost effectiveness over Premixed was 63% for QALY and 41% for LYG. 
CONCLUSIONS: Biphasic insulin aspart improves quality of life what translates to 
higher QALY. Despite higher costs associated with treatment, biphasic insulin aspart 
seems to be cost-effective in Polish setting.
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OBJECTIVES: To evaluate cost-utility of insulin glargine (IGlar) in combination 
therapy with oral antidiabetic drugs (OAD) compared with premix insulin (IMix) 
added to OAD and IMix alone in patients with type 2 diabetes. METHODS: A micro-
simulation DES model was used to estimate utilities and costs. Costs were calculated 
from the National Health Fund (NHF) perspective and form NHF plus patient per-
spective. Simulation was executed in one year cycles and terminated at the time of the 
patient’s death. Transition probabilities between health states were calculated based 
on a systematic review of RCTs and supplemented with published literature if neces-
sary. Health states utilities were taken from published literature. Probabilistic sensitiv-
ity analysis was performed to estimate the probability that IGlar with OAD is cost 
effective in Polish settings (threshold about 91,000 PLN). RESULTS: From NHF per-
spective IGlar added to OADs compared with IMix added to OADs was dominant 
therapy e.g less costly (cost difference PLN2,496) and more effective (QALY difference 
0.19) and from NHF plus patient perspective incremental costs were PLN34,662 per 
QALY gained. When compared with insulin mixtures alone, IGlar added to OADs 
was dominant therapy from NHF perspective e.g less costly (cost difference 
PLN1,1105) and more effective (QALY difference 0.13) and from NHF plus patient 
perspective incremental costs were PLN19,800 per QALY gained. From NHF perspec-
tive the probability of IGlarOAD cost effectiveness over IMixOAD was 96.9%,and 
IGlarOAD over IMix alone was 95.7%. From NHF plus patient perspective the 
probability of IGlar cost effectiveness over IMix with OAD was 86.7% and IGlarOAD 
over IMix alone was 82.8%. CONCLUSIONS: According to this analysis performed 
in Poland, Insulin glargine, when added to OADs, seems to be more cost effective then 
insulin mixture, both in combination with OADs and alone.
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OBJECTIVES: Type 2 diabetes is a difﬁcult disease to manage and treatment is often 
suboptimal for many patients, in particular with insulin therapy. Preﬁlled insulin pens 
provide patients with an easier-to-manage regimen that might lead to improved adher-
ence compared to vial/syringe use. This study analyzed the impact of switching from 
analog insulin in vials to the preﬁlled pen, FlexPen®. METHODS: Real world data 
from a large commercial health plan in the US were investigated and insulin daily 
average consumption (DACON), hypoglycemic events and health care costs were 
analyzed before and after switch to FlexPen®. To control for the general change in 
insulin consumption the FlexPen® cohort was compared to a matched cohort that 
continued analog insulin in vials. RESULTS: A total of 532 patients switched to 
FlexPen® were matched to a cohort continuing on an analog insulin (n  532) admin-
istered by vial/syringe. Insulin DACON increased in both cohorts by 6–10% from the 
12-month pre-period to the 12-month post-period. However, DACON increased 
approximately 2 units more among patients switching to FlexPen® than the vial/
syringe cohort (p  0.0299). In addition, hypoglycemic event rates decreased in the 
FlexPen® cohort from 6.39% in the pre-period to 4.89% in the post-period while 
hypoglycemic events increased in the vial/syringe cohort from 4.89% to 5.83%. 
Despite higher acquisition costs of FlexPen® vs. vials there were no differences in 
pharmaceutical costs (5,414 vs. 4,790; p  0.08) or total costs (13,214 vs. 13,211; p 
 0.95) in the follow-up period. CONCLUSIONS: Patients switched to FlexPen® 
administration experienced an increase in DACON compared to the analog vial 
cohort, which is likely to be associated with improved adherence. Despite increase in 
DACON with FlexPen®, total health care and pharmaceutical costs were similar 
between groups in the follow-up period. Hypoglycemic events decreased in the 
FlexPen® cohort while they increased in the analog vial cohort.
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OBJECTIVES: Few studies have examined the association between medication adher-
ence and age in low income elderly type 2 diabetes patients. The study objective was 
to determine the age associated medication adherence among low-income type-2 dia-
betes patients enrolled in Medicaid. METHODS: This was a retrospective cohort 
study, which compared medication adherence among different age groups of Medicaid 
insured patients with type-2 diabetes newly starting oral antidiabetic medication. The 
study compared the differences in medication adherence among 681 patients aged 
18–44 years, 2327 patients aged 45–64 years and 161 patients aged 65 years newly 
starting antidiabetic medication between July 2001 and June 2002. Medication adher-
ence was measured as medication possession ratio using prescription reﬁll patterns. 
Multiple regression analyses were used to determine the difference in adherence rates 
after adjusting for different covariates. RESULTS: Medication adherence rate was 
signiﬁcantly higher for age group 65 years [0.59 0.31), (p  0.05)] as compared to 
age groups 18–44 years [0.56 (0.31), (p  0.05)] and 44–64 years [0.22 (0.17), (p  
0.05)] respectively. Multiple regression analyses showed that compared to age group 
18–44 years, age groups 65 and 44–64 years had signiﬁcantly higher adherence rate 
by 13.4% and 12.5% respectively. Metformin users were associated with a 34.5% 
decrease in adherence rate as compared to the sulfonylurea users (p  0.05). CON-
CLUSIONS: Better oral antidiabetic medication adherence was associated with 
increased age. Future research should investigate patient-related factors affecting medi-
cation adherence with an emphasis on the development of efﬁcient medication man-
agement therapies which may in turn, reduce health care costs and disease burden in 
low-income elderly diabetic patients.
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OBJECTIVES: To examine the relationship between Hemoglobin A1c (HbA1c) values 
and medication adherence over time in diabetic patients participating in a pharmacist-
conducted Medication Therapy Management program (MTMP). METHODS: This 
study used a prospective, intention-to-treat, pre-post longitudinal design assessing the 
impact of a pharmacist-conducted employer sponsored MTMP on clinical and human-
istic outcomes of employees, their spouses and covered dependents with Type 2 dia-
betes. Enrollment began in January 2008. As an incentive to participate, patients 
received a 3 month supply of medications at the cost of one copay. Pharmacist inter-
ventions included medication therapy reviews, discussing details about patients’ 
disease state and the importance of medication adherence, and informing patients 
about appropriate lifestyle modiﬁcations. HbA1c was measured using the Cholestech 
LDX at the pharmacy every three months and adherence was measured at baseline, 
3 months, and nine months. Patient reported adherence was measured using the 
Morisky scale. Currently, most patients have completed six months in the program 
therefore analysis focused on comparing baseline and the three month time point. A 
Wilcoxon signed-rank test was used to determine changes in HbA1c values over time 
and a Spearman correlation was used to examine any relationship. RESULTS: Patients 
who began the program with uncontrolled HbA1c values experienced a signiﬁcant 
decrease of 0.79% in HbA1c values from baseline to 3 months. Adherence levels 
improved signiﬁcantly from baseline to 3 months (p  0.05). There was a signiﬁcant 
inverse relationship between A1c levels and medication adherence at 3 months (Spear-
man’s R  0.264, A  0.05, N  70). Final results will be presented at the conference. 
CONCLUSIONS: As adherence to medications increased there was a decrease in 
HbA1c values. Patients with improved adherence were able to maintain better 
